Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study

Amanda L Roze des Ordons, Kris Chan, Imran Mirza, Derek R Townsend, Sean M Bagshaw, Amanda L Roze des Ordons, Kris Chan, Imran Mirza, Derek R Townsend, Sean M Bagshaw

Abstract

Background: There is limited epidemiologic data on patients with acute myelogenous (myeloid) leukemia (AML) requiring life-sustaining therapies in the intensive care unit (ICU). Our objectives were to describe the clinical characteristics and outcomes in critically ill AML patients.

Methods: This was a retrospective case-control study. Cases were defined as adult patients with a primary diagnosis of AML admitted to ICU at the University of Alberta Hospital between January 1st 2002 and June 30th 2008. Each case was matched by age, sex, and illness severity (ICU only) to two control groups: hospitalized AML controls, and non-AML ICU controls. Data were extracted on demographics, course of hospitalization, and clinical outcomes.

Results: In total, 45 AML patients with available data were admitted to ICU. Mean (SD) age was 54.8 (13.1) years and 28.9% were female. Primary diagnoses were sepsis (32.6%) and respiratory failure (37.3%). Mean (SD) APACHE II score was 30.3 (10.3), SOFA score 12.6 (4.0) with 62.2% receiving mechanical ventilation, 55.6% vasoactive therapy, and 26.7% renal replacement therapy. Crude in-hospital, 90-day and 1-year mortality was 44.4%, 51.1% and 71.1%, respectively. AML cases had significantly higher adjusted-hazards of death (HR 2.23; 95% CI, 1.38-3.60, p = 0.001) compared to both non-AML ICU controls (HR 1.69; 95% CI, 1.11-2.58, p = 0.02) and hospitalized AML controls (OR 1.0, reference variable). Factors associated with ICU mortality by univariate analysis included older age, AML subtype, higher baseline SOFA score, no change or an increase in early SOFA score, shock, vasoactive therapy and mechanical ventilation. Active chemotherapy in ICU was associated with lower mortality.

Conclusions: AML patients may represent a minority of all critically ill admissions; however, are not uncommonly supported in ICU. These AML patients are characterized by high illness severity, multi-organ dysfunction, and high treatment intensity and have a higher risk of death when compared with matched hospitalized AML or non-AML ICU controls. The absence of early improvement in organ failure may be a useful predictor for mortality for AML patients admitted to ICU.

Figures

Figure 1
Figure 1
Crude K-M survival estimates by group (truncated at 1000 days).
Figure 2
Figure 2
Crude K-M survival estimates by group conditional on survival to hospital discharge (truncated at 1000 days).
Figure 3
Figure 3
Δ SOFA score over first 7 days in ICU stratified by 90-day survival.

References

    1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099–2107. doi: 10.1002/cncr.22233.
    1. Ries LAG, Melbert D, Krapcho M. SEER Cancer Statistics Review 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
    1. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098. doi: 10.1002/cncr.21723.
    1. Sierra J, Martino R, Sanchez B, Pinana JL, Valcarcel D, Brunet S. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplant. 2008;41:425–437. doi: 10.1038/sj.bmt.1705973.
    1. Estopa R, Torres Marti A, Kastanos N, Rives A, Agusti-Vidal A, Rozman C. Acute respiratory failure in severe hematologic disorders. Crit Care Med. 1984;12:26–28. doi: 10.1097/00003246-198401000-00007.
    1. Johnson MH, Gordon PW, Fitzgerald FT. Stratification of prognosis in granulocytopenic patients with hematologic malignancies using the APACHE-II severity of illness score. Crit Care Med. 1986;14:693–697. doi: 10.1097/00003246-198608000-00006.
    1. Lloyd-Thomas AR, Dhaliwal HS, Lister TA, Hinds CJ. Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med. 1986;12:317–324. doi: 10.1007/BF00261745.
    1. Schuster DP, Marion JM. Precedents for meaningful recovery during treatment in a medical intensive care unit. Outcome in patients with hematologic malignancy. Am J Med. 1983;75:402–408. doi: 10.1016/0002-9343(83)90340-6.
    1. Ashkenazi YJ, Kramer BS, Harman E. Short-term outcome among patients with leukemia and lymphoma admitted to a medical intensive care unit. South Med J. 1986;79:1086–1088.
    1. Brunet F, Lanore JJ, Dhainaut JF, Dreyfus F, Vaxelaire JF, Nouira S, Giraud T, Armaganidis A, Monsallier JF. Is intensive care justified for patients with haematological malignancies? Intensive Care Med. 1990;16:291–297. doi: 10.1007/BF01706352.
    1. Merz TM, Schar P, Buhlmann M, Takala J, Rothen HU. Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study. Crit Care. 2008;12:R75. doi: 10.1186/cc6921.
    1. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med. 2003;31:104–112. doi: 10.1097/00003246-200301000-00017.
    1. Rabbat A, Chaoui D, Montani D, Legrand O, Lefebvre A, Rio B, Roche N, Lorut C, Marie JP, Huchon G. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol. 2005;129:350–357. doi: 10.1111/j.1365-2141.2005.05459.x.
    1. Rabe C, Mey U, Paashaus M, Musch A, Tasci S, Glasmacher A, Schmidt-Wolf IG, Sauerbruch T, Dumoulin FL. Outcome of patients with acute myeloid leukemia and pulmonary infiltrates requiring invasive mechanical ventilation-a retrospective analysis. J Crit Care. 2004;19:29–35. doi: 10.1016/j.jcrc.2004.02.006.
    1. Scales DC, Thiruchelvam D, Kiss A, Sibbald WJ, Redelmeier DA. Intensive care outcomes in bone marrow transplant recipients: a population-based cohort analysis. Crit Care. 2008;12:R77. doi: 10.1186/cc6923.
    1. Thakkar SG, Fu AZ, Sweetenham JW, McIver ZA, Mohan SR, Ramsingh G, Advani AS, Sobecks R, Rybicki L, Kalaycio M, Sekeres MA. Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer. 2008;112:2233–2240. doi: 10.1002/cncr.23394.
    1. Tremblay LN, Hyland RH, Schouten BD, Hanly PJ. Survival of acute myelogenous leukemia patients requiring intubation/ventilatory support. Clin Invest Med. 1995;18:19–24.
    1. Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, Nollet J, Steel E, Noens LA, Decruyenaere JM. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med. 2008;34:847–855. doi: 10.1007/s00134-008-1002-2.
    1. Epner DE, White P, Krasnoff M, Khanduja S, Kimball KT, Knaus WA. Outcome of mechanical ventilation for adults with hematologic malignancy. J Investig Med. 1996;44:254–260.
    1. Lloyd-Thomas AR, Wright I, Lister TA, Hinds CJ. Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy. Br Med J (Clin Res Ed) 1988;296:1025–1029. doi: 10.1136/bmj.296.6628.1025.
    1. Peters SG, Meadows JA, Gracey DR. Outcome of respiratory failure in hematologic malignancy. Chest. 1988;94:99–102. doi: 10.1378/chest.94.1.99.
    1. Park HY, Suh GY, Jeon K, Koh WJ, Chung MP, Kim H, Kwon OJ, Kim K, Jang JH, Jung CW. et al.Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leuk Lymphoma. 2008;49:1929–1934. doi: 10.1080/10428190802353609.
    1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. doi: 10.1182/blood-2009-03-209262.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829. doi: 10.1097/00003246-198510000-00009.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart K, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.
    1. Cornet AD, Issa AI, van de Loosdrecht AA, Ossenkoppele GJ, Strack van Schijndel RJ, Groeneveld AB. Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care. Eur J Haematol. 2005;74:511–516. doi: 10.1111/j.1600-0609.2005.00418.x.
    1. Depuydt PO, Benoit DD, Vandewoude KH, Decruyenaere JM, Colardyn FA. Outcome in noninvasively and invasively ventilated hematologic patients with acute respiratory failure. Chest. 2004;126:1299–1306. doi: 10.1378/chest.126.4.1299.
    1. Evison J, Rickenbacher P, Ritz R, Gratwohl A, Haberthur C, Elsasser S, Passweg JR. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. Swiss Med Wkly. 2001;131:681–686.
    1. Ewig S, Torres A, Riquelme R, El-Ebiary M, Rovira M, Carreras E, Rano A, Xaubet A. Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Eur Respir J. 1998;12:116–122. doi: 10.1183/09031936.98.12010116.
    1. Kroschinsky F, Weise M, Illmer T, Haenel M, Bornhaeuser M, Hoeffken G, Ehninger G, Schuler U. Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies. Intensive Care Med. 2002;28:1294–1300. doi: 10.1007/s00134-002-1420-5.
    1. Lamia B, Hellot MF, Girault C, Tamion F, Dachraoui F, Lenain P, Bonmarchand G. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. Intensive Care Med. 2006;32:1560–1568. doi: 10.1007/s00134-006-0286-3.
    1. Massion PB, Dive AM, Doyen C, Bulpa P, Jamart J, Bosly A, Installe E. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med. 2002;30:2260–2270. doi: 10.1097/00003246-200210000-00014.
    1. Silfvast T, Pettila V, Ihalainen A, Elonen E. Multiple organ failure and outcome of critically ill patients with haematological malignancy. Acta Anaesthesiol Scand. 2003;47:301–306. doi: 10.1034/j.1399-6576.2003.00058.x.
    1. Yau E, Rohatiner AZ, Lister TA, Hinds CJ. Long term prognosis and quality of life following intensive care for life-threatening complications of haematological malignancy. Br J Cancer. 1991;64:938–942.
    1. Cherif H, Martling CR, Hansen J, Kalin M, Bjorkholm M. Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication. Support Care Cancer. 2007;15:1393–1398. doi: 10.1007/s00520-007-0268-1.
    1. Hill QA. Intensify, resuscitate or palliate: Decision making in the critically ill patient with haematological malignancy. Blood Rev. 2010;24:17–25. doi: 10.1016/j.blre.2009.10.002.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner